Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Randomized Study of Double Cord Blood Transplantation (CBT) with Versus without Ex-Vivo Expansion (EXP).

Blood (2007) 110 (11): 2014.

https://doi.org/10.1182/blood.V110.11.2014.2014

Published: 2007

Journal Articles

A Dose and Schedule Finding Study of Maintenance Therapy with Low-Dose 5-Azacitidine (AZA) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for High-Risk AML or MDS.

Marcos de Lima, L. Padua, S. Giralt, C. Hosing, K. Komanduri, M. Qazilbash, E.J. Shpall, P. Thall, S. Qureshi, G. McCormick, W. Tong, U. Popat, A. Soriano, R. Champlin, G. Garcia-Manero

Blood (2007) 110 (11): 3012.

https://doi.org/10.1182/blood.V110.11.3012.3012

Published: 2007

Journal Articles

Prophylaxis of Graft-Versus-Host Disease (GVHD) with Pentostatin, Tacrolimus, and “Mini”-Methotrexate (MTX): A Phase I/II Controlled, Randomized Study in Unrelated Donor (UD) Transplantation.

Blood (2007) 110 (11): 40.

https://doi.org/10.1182/blood.V110.11.40.40

Published: 2007

Journal Articles

Long-Term Follow-Up of IV Busulfan (Bu) with Fludarabine (Flu) vs IV Bu with Cyclophosphamide (Cy) as Pre (Allogeneic) Transplant Conditioning Therapy for AML/MDS.

Marcos De Lima, X. Wang, P.F. Thall, D. Couriel, R.B. Jones, E.J. Shpall, U. Popat, S. Giralt, M. Korbling, R. Champlin, B.S. Andersson

Blood (2006) 108 (11): 322.

https://doi.org/10.1182/blood.V108.11.322.322

Published: 2006

Journal Articles

Influence of Allele Level HLA Typing on Unrelated Donor (UD) Transplantation for High Risk Myeloid Leukemias.

S. Parmar, M. Fernandez-Vina, P. Liu, P. Cano, B. S. Andersson, M. Munsell, S. Giralt, J. McMannis, E. J. Shpall, D. Couriel, S. Ghosh, R. Champlin, M. de Lima

Blood (2005) 106 (11): 2916.

https://doi.org/10.1182/blood.V106.11.2916.2916

Published: 2005

Journal Articles

Long-Term Follow-Up of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) with Fludarabine and Melphalan (FM) Reduced Intensity Conditioning (RIC) for High-Risk AML/MDS.

B. Oran, R. Saliba, S. Giralt, D. Couriel, A. Carrasco-Yalan, C. Hosing, M. Shahjahan, E. de Meis, A. Anagnostopoulos, P. Anderlini, S. Ghosh, I. Khouri, R. Champlin, M. de Lima

Blood (2005) 106 (11): 838.

https://doi.org/10.1182/blood.V106.11.838.838

Published: 2005

Journal Articles

Results of a Phase I/II Study of Gemtuzumab Ozogamicin Added to Fludarabine (F), Melphalan (M) and Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Relapsed Myeloid Leukemias.

Marcos de Lima, S. Giralt, Z. Caldera, G. McCormick, M. Qazilbash, P. Anderlini, E. J. Shpall, C. Hosing, M. Donato, S. Kornblau, I. Khouri, T. Martin, D. Couriel, R. Champlin

Blood (2005) 106 (11): 841.

https://doi.org/10.1182/blood.V106.11.841.841

Published: 2005

Journal Articles

Higher Rate of Thrombotic Thrombocytopenic Pupura (TTP) Associated with Graft Versus Host Disease (GVHD) and Unrelated Donor Bone Marrow Transplantation (BMT).

B. Oran, MD, A. Aleman, MD, E. J. Shpall, MD, C. Hosing, MD, M. Korbling, MD, P. Anderlini, MD, R. Champlin, MD, M. Donato, MD

Blood (2005) 106 (11): 1111.

https://doi.org/10.1182/blood.V106.11.1111.1111

Published: 2005

Journal Articles

Phase I/II Study of Gemtuzumab Ozogamicin (GO), Fludarabine and Melphalan (FM) Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in AML/MDS.

M. de Lima, P. Thall, M. Shahjahan, W. Xuemei, D. Couriel, P. Anderlini, C. Hosing, M. Qazilbash, G. McCormick, C. Ippoliti, M. Donato, T. Martin, L. Metoyer, L. Griffin, P. Kebriaei, R. Champlin, S. Giralt

Blood (2004) 104 (11): 1824.

https://doi.org/10.1182/blood.V104.11.1824.1824

Published: 2004

Journal Articles

Pentostatin, Tacrolimus, and “Mini”-Methotrexate for Graft-Versus-Host Disease (GVHD) Prophylaxis: A Phase I/II Controlled, Randomized Study.

M. de Lima, D. Couriel, M. Munsell, M. Westmoreland, H. Shah, J. deJesus, C. Hosing, S. Ghosh, P. Anderlini, J. Gajewski, B. Andersson, S. Kornblau, B. Hocking, C. Ippoliti, S. Giralt, E. Shpall, R. Champlin

Blood (2004) 104 (11): 727.

https://doi.org/10.1182/blood.V104.11.727.727

Published: 2004

Journal Articles

Transplantation of Cord Blood Expanded Ex Vivo with Copper Chelator.

E. Shpall, M. de Lima, K. Chan, R. Champlin, A. Gee, P. Thall, K. Komanduri, D. Couriel, B. Andersson, C. Hosing, S. Giralt, S. Safa Karandish, T. Tara Sadeghi, B. Muriera, T. Peled, F. Grynspan, A. Nagler, J. McMannis

Blood (2004) 104 (11): 982.

https://doi.org/10.1182/blood.V104.11.982.982

Published: 2004

Journal Articles

A Novel Triple Purge Strategy for Eliminating Chronic Myelogenous Leukemia (CML) Cells from Autografts.

H. Yang, C. Eaves, M. de Lima, M. Lee, R. Champlin, J. McMannis, S. Robinson, T. Niu, W. Decker, D. Xing, M. Thomas, J. Ng, S. Li, A. Eaves, R. Jones, B. Andersson, E. Shpall

Blood (2004) 104 (11): 152.

https://doi.org/10.1182/blood.V104.11.152.152

Published: 2004

Journal Articles

Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease

D. Przepiorka, N. A. Kernan, C. Ippoliti, E. B. Papadopoulos, S. Giralt, I. Khouri, J.-G. Lu, J. Gajewski, A. Durett, K. Cleary, R. Champlin, B. S. Andersson, S. Light

Blood (2000) 95 (1): 83–89.

https://doi.org/10.1182/blood.V95.1.83

Published: 2000

Journal Articles

Tacrolimus and minidose methotrexate for prevention of acute graft- versus-host disease after matched unrelated donor marrow transplantation

D Przepiorka, C Ippoliti, I Khouri, M Woo, R Mehra, D Le Bherz, S Giralt, J Gajewski, H Fischer, H Fritsche, AB Deisseroth, K Cleary, R Champlin, K Besien, B Andersson, R Maher, W Fitzsimmons

Blood (1996) 88 (11): 4383–4389.

https://doi.org/10.1182/blood.V88.11.4383.4383

Published: 1996

Journal Articles

Peripheral blood stem cell apheresis in normal donors: the neglected side [letter; comment]

P Anderlini, D Przepiorka, R Champlin, M Korbling

Blood (1996) 88 (9): 3663–3664.

https://doi.org/10.1182/blood.V88.9.3663.bloodjournal8893663

Published: 1996

Journal Articles

Biologic and clinical effects of granulocyte colony-stimulating factor in normal individuals

P Anderlini, D Przepiorka, R Champlin, M Korbling

Blood (1996) 88 (8): 2819–2825.

https://doi.org/10.1182/blood.V88.8.2819.bloodjournal8882819

Published: 1996

Journal Articles

Early myeloablative therapy for multiple myeloma

R Alexanian, MA Dimopoulos, J Hester, K Delasalle, R Champlin

Blood (1994) 84 (12): 4278–4282.

https://doi.org/10.1182/blood.V84.12.4278.bloodjournal84124278

Published: 1994

Journal Articles

Limited value of myeloablative therapy for late multiple myeloma

R Alexanian, M Dimopoulos, T Smith, K Delasalle, B Barlogie, R Champlin

Blood (1994) 83 (2): 512–516.

https://doi.org/10.1182/blood.V83.2.512.512

Published: 1994

Journal Articles

Preparative regimens for autologous bone marrow transplantation [editorial]

R Champlin

Blood (1993) 81 (2): 277–280.

https://doi.org/10.1182/blood.V81.2.277.277

Published: 1993

Journal Articles

Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia

G Schiller, J Gajewski, M Territo, S Nimer, M Lee, T Belin, R Champlin

Blood (1992) 80 (12): 2977–2982.

https://doi.org/10.1182/blood.V80.12.2977.2977

Published: 1992

NARROW

Randomized Study of Double Cord Blood Transplantation (CBT) with Versus without Ex-Vivo Expansion (EXP).

A Dose and Schedule Finding Study of Maintenance Therapy with Low-Dose 5-Azacitidine (AZA) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for High-Risk AML or MDS.

Prophylaxis of Graft-Versus-Host Disease (GVHD) with Pentostatin, Tacrolimus, and “Mini”-Methotrexate (MTX): A Phase I/II Controlled, Randomized Study in Unrelated Donor (UD) Transplantation.

Long-Term Follow-Up of IV Busulfan (Bu) with Fludarabine (Flu) vs IV Bu with Cyclophosphamide (Cy) as Pre (Allogeneic) Transplant Conditioning Therapy for AML/MDS.

Influence of Allele Level HLA Typing on Unrelated Donor (UD) Transplantation for High Risk Myeloid Leukemias.

Long-Term Follow-Up of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) with Fludarabine and Melphalan (FM) Reduced Intensity Conditioning (RIC) for High-Risk AML/MDS.

Results of a Phase I/II Study of Gemtuzumab Ozogamicin Added to Fludarabine (F), Melphalan (M) and Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Relapsed Myeloid Leukemias.

Higher Rate of Thrombotic Thrombocytopenic Pupura (TTP) Associated with Graft Versus Host Disease (GVHD) and Unrelated Donor Bone Marrow Transplantation (BMT).

Phase I/II Study of Gemtuzumab Ozogamicin (GO), Fludarabine and Melphalan (FM) Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in AML/MDS.

Pentostatin, Tacrolimus, and “Mini”-Methotrexate for Graft-Versus-Host Disease (GVHD) Prophylaxis: A Phase I/II Controlled, Randomized Study.

Transplantation of Cord Blood Expanded Ex Vivo with Copper Chelator.

A Novel Triple Purge Strategy for Eliminating Chronic Myelogenous Leukemia (CML) Cells from Autografts.

Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease

Tacrolimus and minidose methotrexate for prevention of acute graft- versus-host disease after matched unrelated donor marrow transplantation

Peripheral blood stem cell apheresis in normal donors: the neglected side [letter; comment]

Biologic and clinical effects of granulocyte colony-stimulating factor in normal individuals

Early myeloablative therapy for multiple myeloma

Limited value of myeloablative therapy for late multiple myeloma

Preparative regimens for autologous bone marrow transplantation [editorial]

Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only